BioCis Pharma Begins Phase IIa Trial in Atopic Dermatitis
BioCis Pharma Oy, a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability and efficacy of the topical product in a total of 18 subjects with mild to moderate forms of atopic dermatitis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.